7th October 2016 - 9th October 2016
Outcome of multiple myeloma has dramatically improved over the last years with the introduction of novel agents. These agents have not only improved the complete remission rates, but they have resulted in tangible improvements in survival.
Upon completion of this CME activity, participants should be able to:
Acquire insight into the current diagnostic process of multiple myeloma, staging system, and risk stratification.
Evaluate the relevance of molecular diagnostics and minimal residual disease assessment, and their relevance for clinical management decisions.
Learn about treatment state of the art, and understand some of the critical clinical management issues in the treatment of young adults and patients of older age with fit or frail conditions.
Get insight into developmental therapeutics of multiple myeloma, Waldestrom macroglobulinemia and amyloidosis including knowledge about mechanisms of action of novel therapeutic compounds, the current status of development of various targeted drugs and their promises for future clinical applications.